Ozempic

Active Ingredient(s): Semaglutide
FDA Approved: * December 5, 2017
Pharm Company: * NOVO NORDISK INC
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Ozempic Overview

Semaglutide (USAN; trade name Ozempic) is a pharmaceutical drug in development by a Danish company Novo Nordisk for the treatment of type 2 diabetes.[1][2] It is marketed by the name Ozempic. As a glucagon-like peptide-1 receptor agonist, it lowers the blood sugar level by increasing the production of insulin. It was discovered in 2012,[3] by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide.[4] Clinical trials were started in 2015, and phase 3 was completed ...

Read more Ozempic Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Semaglutide

Recent Ozempic Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Semaglutide

Solution: 2mg/1.5ml (1.34mg/ml)

Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Ozempic: (2 results)

Sorted by National Drug Code

0169-4132 Ozempic 1.34 mg/ml Subcutaneous Injection, Solution by Novo Nordisk
0169-4136 Ozempic 1.34 mg/ml Subcutaneous Injection, Solution by Novo Nordisk

Other drugs which contain Semaglutide or a similar ingredient: (1 result)

Semaglutide